Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brok-Simoni

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Pediatric small cell variant of Ki-1 (CD30) + T-cell lymphoma with germ-line configuration of the T-cell receptor geneA Toren, Y Neumann, E Rosner, et al.
Journal of Cell Science|October 10, 2001
Nuclear membrane protein LAP2beta mediates transcriptional repression alone and together with its binding partner GCL (germ-cell-less)E Nili, G S Cojocaru, Y Kalma, et al.
Transplantation|October 25, 2000
Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastomaA Toren, A Nagler, G Rozenfeld-Granot, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Pediatric small cell variant of Ki-1 (CD30) + T-cell lymphoma with germ-line configuration of the T-cell receptor geneA Toren, Y Neumann, E Rosner, et al.
Journal of Cell Science|October 10, 2001
Nuclear membrane protein LAP2beta mediates transcriptional repression alone and together with its binding partner GCL (germ-cell-less)E Nili, G S Cojocaru, Y Kalma, et al.
Transplantation|October 25, 2000
Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastomaA Toren, A Nagler, G Rozenfeld-Granot, et al.
Pageof 8